news.ssbcrack.comNov 10$HIMS

Hims Stock Slides After Earnings Miss and Downgraded Outlook Despite Eli Lilly Deal

Hims & Hers Health's stock fell after Q3 earnings missed expectations, with a wider-than-expected loss. The company lowered its 2026 outlook despite a recent deal with Eli Lilly to distribute weight-loss drugs. Investors reacted negatively to the revised projections.

Original reporting

news.ssbcrack.com

Published Nov 10, 2026, 4:53 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 10, 2026, 5:52 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Hims Stock Slides After Earnings Miss and Downgraded Outlook Despite Eli Lilly Deal — source image — Source · news.ssbcrack.com

Decision brief

The 30-second read

$HIMSBearishHigh

Why it matters

The earnings miss and lowered outlook suggest short‑term weakness, but the Eli Lilly deal may provide a longer‑term growth catalyst.

Market read

The stock's slide reflects immediate market reaction to disappointing earnings and guidance, with potential sector ripple effects.

What to watch

Potential revenue from Zepbound and Foundayo distribution not yet reflected in guidance.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Hims & Hers Health is a telehealth provider expanding into weight‑loss medication distribution through a new Eli Lilly partnership.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HIMSBearishHigh confidence

Context

Hims & Hers reported Q3 earnings that missed expectations and lowered its 2026 outlook, causing the stock to slide.

Expected impact

downward pressure as investors price in weaker sales and lower outlook

Evidence & confidence

The article provides the first disclosure of the earnings miss and revised guidance, which are material new facts for the stock.

Market effects

Sector

Telehealth sector may face broader scrutiny as earnings miss highlights growth challenges.

Regional

U.S. market participants may adjust exposure to digital health stocks.

Global

Limited to U.S. listed telehealth companies.

Counterpoint

What could challenge this read

The partnership with Eli Lilly could unlock future upside if execution improves, making the dip a buying opportunity.

Key entities

company
Hims & Hers Health
Telehealth firm reporting Q3 earnings.
company
Eli Lilly
Pharmaceutical partner supplying weight‑loss drugs.

Read at source ← All news

$HIMSMedAI 8/10

Hims & Hers Celebrated Its Eli Lilly Deal, Then Lost a Quarter of Its Value in a Week

Hims & Hers (HIMS) shares fell 25.67% last week, despite a deal with Eli Lilly (LLY) announced on November 6. HIMS reported Q3 revenue of $890.37M, up 48.65%, but margins dropped to 57% from 74%. Lilly's Q3 revenue rose 38.61% to $24.397B, and it raised its full-year outlook to $91B-$92B. HIMS's subscriber base shrank by 100,000 to 2.8M, and it cut full-year Adjusted EBITDA guidance to $257M-$277M.

247wallst.comNov 10

$LLYMed

Morning Business Report: Employers brace for major healthcare cost increases as Eli Lilly reports promising sleep apnea trial

Employers anticipate significant healthcare cost increases, driven by factors like hospital expenses and prescription drug costs. Eli Lilly reported positive trial results for its weight-loss pill in treating sleep apnea, planning U.S. approval by year-end. Nvidia faces a board investigation over CEO allegations. American Express partners with Fanatics for a co-branded credit card.

41nbc.comNov 10

$HIMSHighAI 8/10

Hims & Hers Health Inc (HIMS) (Q3 2026) Earnings Call Highlights: Revenue Surges 49%

Hims & Hers Health Inc. (HIMS) reported Q3 2026 revenue growth of 49%, but subscribers declined by 100,000 to 2.8 million due to reduced marketing. Gross margins fell to 57%, and GAAP net loss was $33 million. Full-year adjusted EBITDA guidance was lowered to $257-$277 million. The company plans to increase marketing and expects subscriber growth to recover in Q1 2027. Management discussed strategic shifts, including peptide launches and international expansion.

finance.yahoo.comNov 10

$HIMSMed

Morgan Stanley maintains Hims & Hers Health at Equal-Weight, lowers price target to $25 from $28

Morgan Stanley kept Hims & Hers Health at Equal-Weight, cutting its price target to $25 from $28, a 10.7% reduction. This implies a 9.0% upside from the Nov 9 close of $22.94, according to the bank.

tradingview.comNov 10

$LLYLow

FDA adds rare vision-loss warning to popular GLP-1 drugs - WSVN 7News

The FDA will add a warning about rare vision loss to GLP-1 drugs like Ozempic and Wegovy. The condition, non-arteritic anterior ischemic optic neuropathy, affects about 6 in 100,000 patients. The FDA acted after a 2024 study linked it to semaglutide, Ozempic's active ingredient. Symptoms include blurred vision and blind spots.

wsvn.comNov 10